Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the 12 Best Genomics Stocks to Invest In. Cathie Wood’s ARK Investment ...

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight ...

RXRX Stock jumps after JPMorgan upgrade and trial data boost, fueling investor optimism in Recursion’s AI drug discovery ...

Recursion Pharmaceuticals presents a compelling investment opportunity due to its AI-driven drug discovery platform, solid financials, and diverse pipeline, setting it apart from competitors like ...

Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will ...

Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced ...

Two of the leading companies in the AI drug development field, Recursion Pharmaceuticals and Exscientia, said Thursday that they will merge into one company. The new company will continue using the ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...